Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]

Status:

In progress

Technology type:

Medicine

Decision:

Selected

Reason for decision:

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources

Process:

STA Standard

ID number:

4067

Project Team

Project lead

Thomas Feist

Email enquiries

If you have any queries please email [email protected]

External Assessment Group:

School of Health and Related Research (ScHARR), University of Sheffield

Stakeholders

Companies sponsors

Sanofi

Others

Department of Health and Social Care

 

NHS England

 

Welsh Government

Patient carer groups

Blood Cancer UK

 

Myeloma UK

Professional groups

Association of Cancer Physicians

 

Cancer Research UK

 

Royal College of Physicians

 

Royal College of Radiologists

 

UK Myeloma Society

Associated public health groups

None

Comparator companies

Advanz Pharma (dexamethasone, lenalidomide) confidentiality agreement not signed, not participating

 

Aspen (dexamethasone) confidentiality agreement not signed, not participating

 

Aspire Pharma (dexamethasone) confidentiality agreement not signed, not participating

 

Bristol Myers Squibb (lenalidomide, pomalidomide) confidentiality agreement not signed, not participating

 

Cipla (lenalidomide) confidentiality agreement not signed, not participating

 

GlaxoSmithKline (belantamab mafodotin) confidentiality agreement not signed, not participating

 

Glenmark Pharmaceuticals (dexamethasone) confidentiality agreement not signed, not participating

 

hameln pharma (dexamethasone) confidentiality agreement not signed, not participating

 

Hospira (dexamethasone) confidentiality agreement not signed, not participating

 

Janssen-Cilag (ciltacabtagene autoleucel, daratumumab) confidentiality agreement not signed, not participating

 

Laboratoires CTRS (dexamethasone) – confidentiality agreement not signed, not participating

 

Martindale Pharma (dexamethasone) – confidentiality agreement not signed, not participating

 

Mylan (lenalidomide) – confidentiality agreement not signed, not participating

 

Noridem Enterprises (dexamethasone) – confidentiality agreement not signed, not participating

 

Panpharma (dexamethasone) – confidentiality agreement not signed, not participating

 

Pfizer (elranatamab) – confidentiality agreement not signed, not participating

 

Piramal Critical Care (lenalidomide) – confidentiality agreement not signed, not participating

 

Ranbaxy (lenalidomide) – confidentiality agreement not signed, not participating

 

Rosemont Pharmaceuticals (dexamethasone) – confidentiality agreement not signed, not participating

 

Sandoz (lenalidomide) – confidentiality agreement not signed, not participating

 

Synchrony Pharma (dexamethasone) – confidentiality agreement not signed, not participating

 

Takeda (ixazomib) – confidentiality agreement not signed, not participating

 

Teva (lenalidomide) – confidentiality agreement not signed, not participating

 

Thame Laboratories (dexamethasone) – confidentiality agreement not signed, not participating

 

Thornton & Ross (lenalidomide) – confidentiality agreement not signed, not participating

 

Wockhardt (dexamethasone) – confidentiality agreement not signed, not participating

 

Zentiva (lenalidomide) – confidentiality agreement not signed, not participating

General commentators

All Wales Therapeutics and Toxicology Centre

 

British National Formulary

 

Department of Health - Northern Ireland

 

Healthcare Improvement Scotland

 

Health Technology Wales (HTW)

 

Medicines and Healthcare products Regulatory Agency

 

NHS Wales Joint Commissioning Committee

 

Scottish Medicines Consortium

Relevant research groups

Institute of Cancer Research

 

National Institute for Health Research

Timeline

Key events during the development of the guidance:

For further information on our processes and methods, please see our CHTE processes and methods manual